HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Verona Pharma (NASDAQ:VRNA) and maintained a price target of $32.
May 15, 2024 | 10:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Verona Pharma and maintained a price target of $32, indicating confidence in the company's future performance.
The reiteration of a Buy rating and a maintained price target of $32 by HC Wainwright & Co. suggests strong confidence in Verona Pharma's future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100